A phase 1 trial of the PARP inhibitor fuzuloparib in combination with the anti-angiogenic apatinib in recurrent ovarian or triple-negative breast cancer.

被引：0
|
作者：
Li, Huiping
Zhang, Jiayang
Yin, Rutie
Song, Nan
Zhang, Youzhong
Zhang, Yu
Zhang, Keqiang
Pan, Hongming
Wang, Ke
Lou, Ge
Li Guiling
Zhang, Ben
Wang, Quanren
Gao, Yunong
机构：
[1] Peking Univ Canc Hosp & Inst, Key Lab Carcinogenesis & Translat Res, Dept Breast Oncol, Minist Educ Beijing, Beijing, Peoples R China
[2] Sichuan Univ, Dept Gynecol & Obstet, West China Univ Hosp 2, Chengdu, Peoples R China
[3] Sichuan Univ, West China Univ Hosp 2, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Minist Educ, Chengdu, Peoples R China
[4] Peking Univ Canc Hosp & Inst, Dept Gynecol Oncol, Key Lab Carcinogenesis & Translat Res, Minist Educ, Beijing, Peoples R China
[5] Shangdong Univ, Dept Obstet & Gynecol, Qilu Hosp, Shandong, Peoples R China
[6] Cent South Univ, Xiangya Hosp, Med Eth Comm, Changsha, Peoples R China
[7] Hunan Canc Hosp, Gynecol Oncol Ward 5, Changsha, Peoples R China
[8] Zhejiang Univ, Dept Med Oncol, Sir Run Run Shaw Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[9] Tianjin Med Univ, Canc Inst & Hosp, Tianjin, Peoples R China
[10] Harbin Med Univ, Gynecol Ward 1, Canc Hosp, Harbin, Peoples R China
[11] Huazhong Univ Sci & Technol, Union Hosp, Dept Gynecol Oncol, Tongji Med Coll, Wuhan, Peoples R China
[12] Jiangsu Hengrui Pharmaceut Co Ltd, Shanghai, Peoples R China
[13] Beijing Canc Hosp, Beijing, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 40卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5539
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Role of CD44v6 in acquired resistance to anti-angiogenic therapy of triple-negative breast cancer
    Morello, Virginia
    Ginestier, Christophe
    Charafe-Jauffret, Emmanuelle
    Michieli, Paolo
    MOLECULAR CANCER RESEARCH, 2013, 11
  • [32] Erratum to: A novel vaccinia virus with dual oncolytic and anti-angiogenic therapeutic effects against triple-negative breast cancer
    Sepideh Gholami
    Andrew Marano
    Nanhai G. Chen
    Richard J. Aguilar
    Alexa Frentzen
    Chun-Hao Chen
    Emil Lou
    Sho Fujisawa
    Clarisse Eveno
    Laurence Belin
    Pat Zanzonico
    Aladar Szalay
    Yuman Fong
    Breast Cancer Research and Treatment, 2016, 156 : 607 - 608
  • [33] Phase I/IB trial of eribulin and everolimus in patients with triple-negative metastatic breast cancer.
    Luu, Thehang H.
    Blanchard, Suzette
    Yim, John Hosei
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer
    Rebecca A Dent
    Geoffrey J Lindeman
    Mark Clemons
    Hans Wildiers
    Arlene Chan
    Nicole J McCarthy
    Christian F Singer
    Elizabeth S Lowe
    Claire L Watkins
    James Carmichael
    Breast Cancer Research, 15
  • [35] Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first-or second-line treatment of patients with metastatic triple-negative breast cancer
    Dent, Rebecca A.
    Lindeman, Geoffrey J.
    Clemons, Mark
    Wildiers, Hans
    Chan, Arlene
    McCarthy, Nicole J.
    Singer, Christian F.
    Lowe, Elizabeth S.
    Watkins, Claire L.
    Carmichael, James
    BREAST CANCER RESEARCH, 2013, 15 (05)
  • [36] Combination benefit between PARP inhibitor niraparib and angiogenesis inhibitors in PDX models of triple-negative breast cancer (TNBC).
    Zhou, Yinghui
    Wang, Sarah
    Mikule, Keith
    Ramaswamy, Sridhar
    Hanke, Jeffrey
    Wang, Jing Yu
    MOLECULAR CANCER RESEARCH, 2018, 16 (08) : 32 - 33
  • [37] Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
    Chee Khoon Lee
    Clare Scott
    Geoffrey J. Lindeman
    Anne Hamilton
    Elizabeth Lieschke
    Emma Gibbs
    Rebecca Asher
    Heath Badger
    Robin Paterson
    Lauren Macnab
    Edmond Michael Kwan
    Prudence A. Francis
    Frances Boyle
    Michael Friedlander
    British Journal of Cancer, 2019, 120 : 279 - 285
  • [38] Phase 1 trial of olaparib and oral cyclophosphamide in BRCA breast cancer, recurrent BRCA ovarian cancer, non-BRCA triple-negative breast cancer, and non-BRCA ovarian cancer
    Lee, Chee Khoon
    Scott, Clare
    Lindeman, Geoffrey J.
    Hamilton, Anne
    Lieschke, Elizabeth
    Gibbs, Emma
    Asher, Rebecca
    Badger, Heath
    Paterson, Robin
    Macnab, Lauren
    Kwan, Edmond Michael
    Francis, Prudence A.
    Boyle, Frances
    Friedlander, Michael
    BRITISH JOURNAL OF CANCER, 2019, 120 (03) : 279 - 285
  • [39] Efficacy and safety of anti-PD-1 antibody SHR-1210 combined with apatinib in patients with advanced triple-negative breast cancer.
    Liu, Jieqiong
    Jiang, Zefei
    Li, Qian
    Li, Ying
    Liu, Qiang
    Song, Erwei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [40] Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer.
    Nelson, Blessie Elizabeth
    Saleem, Sadia
    Damodaran, Senthil
    Somaiah, Neeta
    Piha-Paul, Sarina Anne
    Moore, Julia Ann
    Yilmaz, Bulent
    Karp, Daniel D.
    Dumbrava, Ecaterina Elena
    Tsimberidou, Apostolia Maria
    Hong, David S.
    Ahnert, Jordi Rodon
    Booser, Daniel J.
    Ibrahim, Nuhad K.
    Conley, Anthony Paul
    Bhosale, Priya
    Hernandez, Cristhiam Mauricio Rojas
    Tripathy, Debu
    Naing, Aung
    Meric-Bernstam, Funda
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345